Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02YIP
|
|||
| Former ID |
DIB005791
|
|||
| Drug Name |
AbGn-168
|
|||
| Synonyms |
AbGn-168H; Antibody 168 (autoimmune diseases), Boehringer Ingelheim/AbGenomics; Anti-CD162 mAb (psoriasis), Boehringer/AbGenomics
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Allergy [ICD-11: 4A80-4A85; ICD-10: T78.4; ICD-9: 995.3] | Phase 2 | [1] | |
| Company |
Abgenomics international
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | P-selectin glycoprotein ligand 1 (SELPLG) | Target Info | . | [2] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Staphylococcus aureus infection | ||||
| Pathway Interaction Database | amb2 Integrin signaling | |||
| Reactome | Cell surface interactions at the vascular wall | |||
| WikiPathways | Human Complement System | |||
| Cell surface interactions at the vascular wall | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01855880) Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Avarx. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.